{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:57:53Z","timestamp":1740171473453,"version":"3.37.3"},"reference-count":18,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0618-9","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T04:55:30Z","timestamp":1558500930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer"],"prefix":"10.1136","volume":"7","author":[{"given":"Jacob J.","family":"Adashek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Nazareth Aguiar","family":"Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Galanina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"issue":"3","key":"618_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","volume":"10","author":"MP Thompson","year":"2004","unstructured":"Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10(3):803\u201321.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"618_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446\u201353.","journal-title":"Lancet Oncol"},{"key":"618_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","volume":"5","author":"JD Sandoval-Sus","year":"2017","unstructured":"Sandoval-Sus JD, Mogollon-Duffo F, Patel A, et al. Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017;5:49.","journal-title":"J Immunother Cancer."},{"issue":"10","key":"618_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","volume":"6","author":"N Galanina","year":"2018","unstructured":"Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade. Cancer Immunol Res. 2018;6(10):1129\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"618_CR5","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","volume":"28","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Schlaak M, Eigentler TK, et al. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann Oncol. 2017;28(12):3104\u20136.","journal-title":"Ann Oncol"},{"key":"618_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctro.2018.12.004","volume":"15","author":"A Linge","year":"2019","unstructured":"Linge A, Rauschenberg R, Blum S, Spornraft-Ragaller P, Meier F, Troost EGC. Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. Clin Transl Radiat Oncol. 2019;15:42\u20135.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"618_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2019","unstructured":"Boichard A, Pham TV, Yeerna H, et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019;8(3):1550341.","journal-title":"Oncoimmunology."},{"issue":"3","key":"618_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284719","volume":"6","author":"A Boichard","year":"2017","unstructured":"Boichard A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology. 2017;6(3):e1284719.","journal-title":"Oncoimmunology."},{"issue":"7109","key":"618_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134.","journal-title":"Nature."},{"key":"618_CR10","doi-asserted-by":"crossref","unstructured":"Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Transl Oncol. 2018.","DOI":"10.1007\/s12094-018-1981-6"},{"issue":"11","key":"618_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/ni1515","volume":"8","author":"DE Kaufmann","year":"2007","unstructured":"Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8(11):1246\u201354.","journal-title":"Nat Immunol"},{"key":"618_CR12","first-page":"229","volume":"371","author":"K McFadden","year":"2013","unstructured":"McFadden K, Luftig MA. Interplay between DNA tumor viruses and the host DNA damage response. Curr Top Microbiol Immunol. 2013;371:229\u201357.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"11","key":"618_CR13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","volume":"14","author":"DE Speiser","year":"2014","unstructured":"Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol. 2014;14(11):768\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"618_CR14","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"11","key":"618_CR15","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"618_CR16","doi-asserted-by":"crossref","unstructured":"Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage Cancer: a systematic review. JAMA Oncol. 2019.","DOI":"10.1001\/jamaoncol.2018.6737"},{"issue":"1","key":"618_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"618_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/COH.0000000000000321","volume":"12","author":"RF Little","year":"2017","unstructured":"Little RF. Cancer clinical trials in persons with HIV infection. Curr Opin HIV AIDS. 2017;12(1):84\u20138.","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0618-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:19Z","timestamp":1601055859000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0618-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"n\/a","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"n\/a","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JJA has no disclosures. RK has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, and Soluventis); Speaker\u2019s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, and OmniSeq [All institutional]); Board Member (CureMatch, Inc). NG has no disclosures. PNA reports speaker fees from Merck, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"130"}}